drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific T-cell engager antibody)
drug_description
Bispecific T-cell engager antibody that binds CD19 on B cells and CD3 on T cells to form an immune synapse, activate TCR/CD3 signaling, and redirect endogenous T cells to kill CD19-positive malignant B cells.
nci_thesaurus_concept_id
C200070
nci_thesaurus_preferred_term
Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978
nci_thesaurus_definition
A half-life extended T-cell engaging bispecific antibody comprised of a single chain variable fragment (scFv) targeting the tumor-associated antigen (TAA) CD19, a scFv targeting the T-cell surface antigen CD3, and a single-domain heavy chain variable domain (VHH)-based antibody specific for human serum albumin (HSA), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 T-cell engaging bispecific antibody CLN-978 targets and binds to both CD19 antigen expressed on tumor cells and CD3 antigen expressed on T-cells. This results in the cross-linking of T-cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. The HSA binding domain prolongs the half-life of CLN-978.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Bispecific antibody that simultaneously binds CD19 on B cells and CD3 on T cells, forming an immune synapse to activate TCR/CD3 signaling and redirect endogenous T cells to kill CD19-positive malignant B cells; includes an albumin-binding domain to extend half-life.
drug_name
CLN-978
nct_id_drug_ref
NCT05879744